Genetic basis of abnormal B cell development

Current Opinion in Immunology

Volumn 10, Issue 4, 1998, Pages 399-406

  Conley, Mary Ellen ^a   Cooper, Max D ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 3; PROTEIN TYROSINE KINASE;

B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CELL MATURATION; COMMON VARIABLE IMMUNODEFICIENCY; GENE LOCUS; GENE MUTATION; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE DEFICIENCY; IMMUNOGLOBULIN A DEFICIENCY; MOUSE; NONHUMAN; REVIEW; X LINKED AGAMMAGLOBULINEMIA;

EID: 0032146708     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(98)80112-X     Document Type: Article

References (76)

1. of special interest Rosen FS, Wedgwood RJ, Eibl MM, Fisher A, Aiuti F, Notarangelo L, Kishimoto T, Resnick IB, Hammarstrom L, Seger R, et al. Primary immunodeficiency diseases: report of a WHO scientific group. Clin Exp Immunol. 109:1997;S1-S28 This is a current and comprehensive classification of human immunodeficiency diseases.
2. Flori NM, Llambi JM, Boren TE, Borja SR, Casariego GF. Primary immunodeficiency syndrome in Spain: first report of the national Registry in Children and Adults. J Clin Immunol. 17:1997;333-339.
3. Zelazko M, Carneiro-Sampaio M, De Luigi MC, De Olarte DG, Madrigal OP, Perez RB, Cabello A, Rostan MV, Sorensen RU. Primary immunodeficiency diseases in Latin America: first report from eight countries participating in the LAGID. J Clin Immunol. 18:1998;161-166.
4. Burrows PD, Cooper MD. IgA deficiency. Adv Immunol. 65:1997;245-276.
5. Johnson ML, Keeton LG, Zhu ZB, Volanakis JE, Cooper MD, Schroeder HW Jr. Age-related changes in serum immunoglobulins in patients with familial IgA deficiency and common variable immunodeficiency (CVID). Clin Exp Immunol. 108:1997;477-483.
6. Farrington M, Grosmaire LS, Nonoyama S, Fischer SH, Hollenbaugh D, Ledbetter JA, Noelle RJ, Aruffo A, Ochs HD. CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency. Proc Natl Acad Sci USA. 91:1994;1099-1103.
7. of special interest Kondratenko I, Amlot PL, Webster ADB, Farrant J. Lack of specific antibody response in common variable immunodeficiency (CVID) associated with failure in production of antigen-specific memory T cells. Clin Exp Immunol. 108:1997;9-13 This reports that immunization of CVID patients with the neoantigen, keyhole-limpet hemocyanin, failed to elicit the normal increase in responsive T cells, thereby supporting earlier evidence of defective T cell antigen responsiveness. Defective IgM responses to the T-independent antigen, dinitrophenol-Ficoll in the affected individuals do, however, give further evidence of the complicated phenotype of CVID patients.
8. of special interest Thon V, Eggenbauer H, Wolf HM, Fischer MB, Litzman J, Lokaj J, Eibl MM. Antigen presentation by common variable immunodeficiency (CVID) B cells and monocytes is unimpaired. Clin Exp Immunol. 108:1997;1-8 These investigators, whose previous studies point to a defect in T cell responses in CVID, exclude identifiable defects in the antigen-presenting capability of CVID B cells and monocytes.
9. Majolini MB, D'Elios MM, Boncristiano M, Galieni P, Del Prete G, Telford JL, Baldari CT. Uncoupling of T-cell antigen receptor and downstream protein tyrosine kinases in common variable immunodeficiency. Clin Immunol Immunopathol. 84:1997;98-102.
10. Macaulay AE, DeKruyff RH, Umetsu DT. Antigen-primed T cells from B cell-deficient JHD mice fail to provide B cell help. J Immunol. 160:1998;1694-1700.
11. Langhorne J, Cross C, Seixas E, Li C, von der Weid T. A role for B cells in the development of T cell helper function in a malaria infection in mice. Proc Natl Acad Sci USA. 95:1998;1730-1734.
12. Maecker HT, Do M-S, Levy S. CD81 on B cells promotes interleukin 4 secretion and antibody production during T helper type 2 immune responses. Proc Natl Acad Sci USA. 95:1998;2458-2462.
13. Vořechovský I, Zetterquist H, Paganelli R, Koskinen S, Webster ADB, Björkander J, Smith CI, Hammarström L. Family and linkage study of selective IgA deficiency and common variable immunodeficiency. Clin Immunol Immunopathol. 77:1995;185-192.
14. of special interest Cucca F, Zhu Z-B, Khanna A, Cossu F, Congia M, Badiali M, Lampis R, Frau F, de Virgiliis S, Cao A, et al. Evaluation of IgA deficiency in Sardinians indicates a susceptibility gene is encoded within the HLA class III region. Clin Exp Immunol. 111:1998;76-80 IgAD has been associated with the North European haplotype, HLA-A1, -B8, -DR3, with ~13% of humozygous individuals having IgAD. In contrast, normal IgA levels were found in all 43 HLA-DR3-homozygous Sardinians who had insulin-dependent diabetes mellitus or coeliac disease. As the Sardinian HLA-DR3 haplotype diverges from the common Northern European HLA-DR3 haplotype telomeric to the HLA-DR region, these data mitigate against the hypothesis that a class II region allele confers susceptibility to IgAD.
15. of special interest Schroeder HW Jr, Zhu Z-B, March RE, Campbell RD, Berney SM, Nedospasov SA, Turetskaya RL, Atkinson TP, Go RCP, Cooper MD, Volanakis JE. Susceptibility locus for IgA deficiency and common variable immunodeficiency in the HLA-DR3, -B8, -A1 haplotypes. Mol Med. 4:1998;72-86 Earlier work suggested that a susceptibility gene or genes exist for both CVID and IgAD within the MHC class III region in linkage disequilibrium with class I and/or class II alleles. In this study of 73 members of one large family, all immunoglobulin-deficient members shared at minimum a common fragment of the Northern European HLA-A1, -B8, -DR3 haplotype. A susceptibility locus was thus identified for IgAD/CVID which has 21 known genes, including the genes for TNF-α, lymphotoxin (LT)-α and LT-β.
16. Mullighan CG, Fanning GC, Chapel HM, Welsh KI. TNF and lymphotoxin-α polymorphisms associated with common variable immunodeficiency: role in the pathogenesis of granulomatous disease. J Immunol. 159:1997;6236-6241.
17. Sacca R, Cuff CA, Ruddle NH. Mediators of inflammation. Curr Opin Immunol. 9:1997;851-857.
18. Gruen JR, Weissman SM. Evolving views of the major histocompatibility complex. Blood. 90:1997;4252-4265.
19. Smith CIE, Islam KB, Vorechovský I, Olerup O, Wallin E, Rabbani H, Baskin B, Hammarström L. X-linked agammaglobulinemia and other immunoglobulin deficiencies. Immunol Rev. 138:1994;159-183.
20. Yel L, Minegishi Y, Coustan-Smith E, Buckley RH, Trubel H, Pachman LM, Kitchingman GR, Campana, Rohrer J, Conley ME. Mutations in the mu heavy-chain gene in patients with agammaglobulinemia. N Engl J Med. 335:1996;1486-1493.
21. Pan Q, Lindersson Y, Sieras P, Hammarström L. Structural analysis of human γ3 intervening regions and switch regions: implication for the low frequency of switching in IgG3-deficient patients. Eur J Immunol. 27:1997;2920-2926.
22. Tashita H, Fukao T, Kaneko H, Teramoto T, Inoue R, Kasahara K, Kondon N. Molecular basis of selective IgG2 deficiency. J Clin Invest. 101:1998;677-681.
23. Kaisho T, Shwenk F, Rajewsky K. The roles of γ1 heavy chain membrane expression and cytoplasmic tail in IgG1 responses. Science. 276:1997;412-415.
24. Vetrie D, Vořechovský I, Sideras P, Holland J, Davies A, Flinter F, Hammarström L, Kinnon C, Levinsky R, Bobrow M, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature. 361:1993;226-233.
25. Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, Klisak I, Sparkes RS, Kubagawa H, Mohandas T, Quan S, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell. 72:1993;279-290.
26. Thomas JD, Sideras P, Smith CIE, Vořechovský I, Chapman V, Paul WE. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science. 261:1993;355-358.
27. Rawlings DJ, Scharenberg AM, Park H, Wahl MI, Lin S, Kato RM, Fluckiger A-C, Witte ON, Kinet J-P. Activation of BTK by phosphorylation mechanism initiated by SRC family kinases. Science. 271:1996;822-825.
28. Conley ME, Parolini O, Rohrer J, Campana D. X-linked agammaglobulinemia: new approaches to old questions based on the identification of the defective gene. Immunol Rev. 138:1994;5-21.
29. Khan W, Alt FW, Gerstin RM, Malynn BA, Larsson I, Rathbun G, Davidson L, Müller S, Kantor AB, Herzenberg A, et al. Defective B cell development and function in Btk-deficient mice. Immunity. 3:1995;283-299.
30. Kerner JD, Appleby MW, Mohr RN, Chien S, Rawlings DJ, Maliszewski CR, Witte ON, Perlmutter RM. Impaired expansion of mouse B cell progenitors lacking Btk. Immunity. 3:1995;301-312.
31. Hendriks RW, de Bruijn MFTR, Maas A, Dingjan GM, Karis A, Grosveld F. Inactivation of Btk by insertion of IacZ reveals defects in B cell development only past the pre-B cell stage. EMBO J. 15:1996;4862-4872.
32. Kluppel M, Donoviel DB, Brunkow ME, Motro B, Bernstein A. Embryonic and adult expression patterns of the Tec tyrosine kinase gene suggest a role in megakaryocytopoiesis, blood vessel development, and melanogenesis. Cell Growth Differ. 8:1997;1249-1256.
33. Gibson S, Truitt K, Lu Y, Lapushin R, Khan H, Imboden JB, Mills GB. Efficient CD28 signalling leads to increases in the kinase activities of the TEC family tyrosine kinase EMT/ITK/TSK and the SRC family tyrosine kinase LCK. Biochem J. 330:1998;1123-1128.
34. Liao XC, Littman DR, Weiss A. Itk and Fyn make independent contributions to T cell activation. J Exp Med. 186:1997;2069-2073.
35. Saharinen P, Ekman N, Sarvas K, Parker P, Alitalo K, Silvennoien O. The Bmx tyrosine kinase induces activation of the Stat signaling pathway, which is specifically inhibited by protein kinase Cδ Blood. 90:1997;4341-4353.
36. Weil D, Power MA, Smith SI, Li CL. Predominant expression of murine Bmx tyrosine kinase in the granulo-monocytic lineage. Blood. 90:1997;4332-4340.
37. Kitanaka A, Mano H, Conley ME, Campana D. Expression and activation of the nonreceptor tyrosine kinase Tec in human B cells. Blood. 91:1998;940-948.
38. Li T, Rawlings DJ, Park H, Kato RM, Witte ON, Satterthwaite AB. Constitutive membrane association protentiates activation of Bruton tyrosine kinase. Oncogene. 15:1997;1375-1383.
39. Hyvönen M, Saraste M. Structure of the PH domain and Btk motif from Bruton's tyrosine kinase: molecular explanations for X-linked agammaglobulinaemia. EMBO J. 16:1997;3396-3404.
40. Yao L, Suzuki H, Ozawa K, Deng J, Lehel C, Fukamachi H, Anderson WB, Kawakami Y, Kawakami T. Interactions between protein kinase C and pleckstrin homology domains. Inhibition by phosphatidylinositol 4,5-bisphosphate and phorbol 12-myristate 13-acetate. J Biol Chem. 272:1997;13033-13039.
41. Fukuda M, Kojima T, Kabayama H, Mikoshiba K. Mutation of the pleckstrin homology domain of Bruton's tyrosine kinase in immunodeficiency impaired inositol 1,3,4,5-tetrakisphosphate binding capacity. J Biol Chem. 271:1996;30303-30306.
42. Rameh LE, Arvidsson AK, Carraway KL III, Couvillon AD, Rathbun G, Crompton A, VanRenterghem B, Czeck MP, Ravichandran KS, Burakoff SJ, et al. A comparative analysis of the phosphoinositide binding specificity of pleckstrin homology domains. J Biol Chem. 272:1997;22059-22066.
43. Langhans-Rajasekaran IA, Wan Y, Huang X-Y. Activation of Tsk and Btk tyrosine kinases by G protein βγ subunits. Proc Natl Acad Sci USA. 92:1995;8601-8605.
44. Bence K, Ma W, Kozasa T, Huang X-Y. Direct simulation of Bruton's tyrosine kinase by Gq-protein α-subunit. Nature. 389:1997;296-299.
45. Wahl MI, Fluckiger A-C, Kato RM, Park H, Witte ON, Rawlings DJ. Phosphorylation of two regulatory tyrosine residues in the activation of Bruton's tyrosine kinase via alternative receptors. Proc Natl Acad Sci USA. 94:1997;11526-11533.
46. Li Z, Wahl MI, Eguinoa A, Stephens LR, Hawkins PT, Witte ON. Phosphatidylinositol 3-kinase-γ activates Bruton's tyrosine kinase in concert with Src family kinases. Proc Natl Acad Sci USA. 94:1997;13820-13825.
47. Takata M, Kurosaki T. A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-γ2. J Exp Med. 184:1996;31-40.
48. + following B-cell receptor activation. EMBO J. 17:1998;1973-1985 These authors evaluated a series of Epstein-Barr-virus-transformed cell lines from patients with null mutations in Bruton's tyrosine kinase (Btk) and found decreased extracellular calcium influx following cross-linking of surface IgM. As calcium is known to play a role in cell-cycle control and in the activation of several transcription factors, this finding suggests a mechanism by which mutations in Btk could affect B cell development at multiple stages of differentiation.
49. of special interest Yaang W, Desiderio S. BAP-135, a target for Bruton's tyrosine kinase in response to B cell receptor engagement. Proc Natl Acad Sci USA. 94:1997;604-609 These authors identified a protein that could be co-precipitated with Btk in the human B cell line RAMOS. They used tryptic digests of this protein and the GenBank dbEST data to clone the gene for the protein, 957 amino acids in length, that they called BAP-135 (Btk-associated protein of 135 kDa). This protein has several notable features including six copies of a repeat with 90-95 amino acids and two Src phosphorylation sites. When both proteins were over-expressed in a cell line, BAP-135 was phosphorylated if the Btk had an active kinase domain but not if the kinase domain was inactive.
50. Roy AL, Du H, Gregor PD, Novina CD, Martinez E, Roeder RG. Cloning of an Inr- and E-box-binding protein, TFII-I, that interacts physically and functionally with USF1. EMBO J. 16:1997;7091-7104.
51. of special interest Grueneberg DA, Henry RW, Brauer A, Novina CD, Cheriyath V, Roy AL, Gilman M. A multifunctional DNA-binding protein that promotes the formation of serum response factor/homeodomain complexes: identity to TFII-I. Genes Dev. 11:1997;2482-2493 References [50] and [51] describe the cloning of a DNA-binding factor, TRII-I, that is identical to BAP-135, described in [49]. This protein functions synergistically with other transcription factors to organize and stabilize the initiation complex that controls transcription at a variety of sites including the c-fos promoter.
52. of special interest Drabek D, Raguz S, De Wit TPM, Dingjan GM, Savelkoul HFJ, Grosveld F, Hendriks RW. Correction of the X-linked immunodeficiency phenotype by transgenic expression of human Bruton tyrosine kinase under the control of the class II major histocompatibility complex Ea locus control region. Proc Natl Acad Sci USA. 94:1997;610-615 The authors corrected the defect in Btk-deficient mice with a transgene expressing human Btk driven by an MHC class II regulatory element. The results indicate that tight regulation of Btk production is not required to improve B cell function. This observation bodes well for strategies using gene therapy to treat patients with X-linked agammaglobulinemia.
53. Maas A, Dingjam GM, Savelkoul HFJ, Kinnon C, Grosveld F, Hendriks RW. The X-linked immunodeficiency defect in the mouse is corrected by expression of human Bruton's tyrosine kinase from a yeast artificial chromosome trangene. Eur J Immunol. 27:1997;2180-2187.
54. Oeltjen JC, Malley TM, Muzny M, Miller W, Gibbs RA, Belmont JW. Large-scale comparative sequence analysis of the human and murine Bruton's tyrosine kinase loci reveals conserved regulatory domains. Genome Res. 7:1997;315-329.
55. Rohrer J, Conley ME. Transcriptional regulatory elements within the first intron of Bruton's tyrosine kinase. Blood. 91:1998;214-221.
56. Satterthwaite AB, Cheroutre H, Khan WN, Sideras P, Witte ON. Btk dosage determines sensitivity to B cell antigen receptor cross-linking. Proc Natl Acad Sci USA. 94:1997;13152-13157.
57. Vihinen M, Brandau O, Branden LJ, Kwan S-P, Lappalainen I, Lester T, Noordzij JG, Ochs HD, Ollila J, Pienaar SM, et al. BTKbase, mutation database for X-linked agammaglobulinemia (XLA). Nucleic Acids Res. 26:1998;242-247.
58. of special interest Conley ME, Mathias D, Treadaway J, Minegishi Y, Rohrer J. Mutations in Btk in patients with presumed X-linked agammaglobulinemia. Amer J Hum Genet. 62:1998;1034-1045 The authors describe genetic studies on 101 unrelated families in which the affected male was presumed to have XLA. The studies indentified 83 different mutations in Bruton's tyrosine kinase (Btk) in 94 families. Of the remaining families, only one was likely to have mutations in Btk based on the absence of Btk protein in peripheral blood mononuclear cells. These findings indicate that over 90% of patients with early onset infections and absent B cells have easily detectable mutations in Btk. The remaining patients are heterogeneous.
59. of special interest Minegishi Y, Coustan-Smith E, Wang Y-H, Cooper MD, Campana MD, Conley ME. Mutations in the human λ5/14.1 gene result in B cell deficiency and agammaglobulinemia. J Exp Med. 187:1998;71-77 This reports that a patient with less than 1% of the normal number of B cells was found to have mutations in the gene for λ5/14.1. Pre-B cells from this patient were negative for VpreB, indicating that in the absence of λ5/14.1, VpreB is unstable.
60. Saha BK, Curtis SK, Vogler LB, Vihinen M. Molecular and structural characterization of five novel mutations in the Bruton's tyrosine kinase gene from patients with X-linked agammaglobulinemia. Mol Med. 3:1997;477-485.
61. Vořechovský I, Luo L, Hertz JM, Frøland SS, Klemola T, Fiorini M, Quinti I, Paganelli R, Ozsahin H, Hammarström L, et al. Mutation pattern in the Bruton's tyrosine kinase gene in 26 unrelated patients with X-linked agammaglobulinemia. Hum Mutat. 9:1997;418-425.
62. Haire RN, Ohta Y, Strong SC, Litman RT, Liu Y, Prchal JT, Cooper MD, Litman GW. Unusual patterns of exon skipping in Bruton tyrosine kinase are associated with mutations involving the intron 17 3′ splice site. Amer J Hum Genet. 60:1997;798-807.
63. Vihinen M, Nore BF, Mattsson PT, Bäckesjö C-M, Nars M, Koutaniemi S, Watanabe C, Lester T, Jones A, Ochs HD, Smith CIE. Missense mutations affecting a conserved cysteine pair in the TH domain of Btk. FEBS Lett. 413:1997;205-210.
64. Brooimans RA, van den Berg AJAM, Rijkers GT, Sanders LAM, van Amstel JKP, Tilanus MGJ, Grubben MJAL, Zegers BJM. Identification of novel Bruton's tyrosine kinase mutations in 10 unrelated subjects with X linked agammaglobulinaemia. J Med Genet. 34:1997;484-488.
65. De Weers M, Dingjan GM, Brouns GS, Kraakman MEM, Mensink RGJ, Lovering RC, Schuurman RKB, Borst J, Hendriks RW. Expression of Bruton's tyrosine kinase in B lymphoblastoid cell lines from X-linked agammaglobulinaemia patients. Clin Exp Immunol. 107:1997;235-240.
66. Gaspar HB, Lester T, Levinsky RJ, Kinnon C. Bruton's tyrosine kinase expression and activity in X-linked agammaglobulinaemia (XLA): the use of protein analysis as a diagnostic indicator of XLA. Clin Exp Immunol. 111:1998;334-338.
67. of special interest Futatani T, Miyawaki T, Tsukada S, Hashimoto S, Kunikata T, Arai S, Kurimoto M, Niida Y, Matsuoka H, Sakiyama Y, et al. Deficient expression of Bruton's tyrosine kinase in monocytes from X-linked agammaglobulinemia as evaluated by a flow cytometric analysis and its clinical application to carrier detection. Blood. 91:1998;595-602 This reports that of a total of 41 patients with X-linked agammaglobulinemia, 40 had markedly diminished or absent Btk protein in mononuclear cells. This suggests that the vast majority of Btk mutations result in unstable Btk message or protein and dominant-negative mutations in Btk are unlikely to disrupt attempts to treat patients with gene therapy.
68. Holinski-Feder E, Weiss M, Brandau O, Jedele KB, Nore B, Bäckesjö CM, Vihinen M, Hubbard SR, Belohradsky BH, Smith CIE, Meindl A. Mutation screening of the BTK gene in 56 families with X-linked agammaglobulinemia (XLA): 47 unique mutations without correlation to clinical course. Pediatrics. 101:1998;276-284.
69. Conley ME, Fitch-Hilgenberg ME, Cleveland JL, Parolini O, Rohrer J. Screening of genomic DNA to identify mutations in the gene for Bruton's tyrosine kinase. Hum Mol Genet. 3:1994;1751-1756.
70. Jin H, Webster ADB, Vihinen M, Sieras P, Vorechovský I, Hammarström L, Bernatowska-Matuszkiewicz E, Smith CIE, Bobrow M, Vetrie D. Identification of Btk mutations in 20 unrelated patients with X-linked agammaglobulinaemia (XLA). Hum Mol Genet. 4:1995;693-700.
71. Saffran D, Parolini O, Fitch-Hilgenberg ME, Rawlings DJ, Afar DEH, Witte ON, Conley ME. brief report: a point mutation in the SH2 domain of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia. N Engl J Med. 330:1994;1488-1491.
72. Bykowsky MJ, Haire RN, Ohta Y, Tang H, Sung S-SJ, Veksler ES, Greene JM, Fu SM, Litman GW, Sullivan KE. Discordant phenotype in siblings with X-linked agammaglobulinemia. Amer J Hum Genet. 58:1996;477-483.
73. 145ΔStop) in Bruton's tyrosine kinase is associated with newly diagnosed X-linked agammaglobulinemia in a 51-year-old male. Mol Med. 2:1996;619-623.
74. Oka Y, Rolink AG, Andersson J, Kamanaka M, Uchia J, Yasui T, Kishimoto T, Kikutani H, Melchers F. Profound reduction of mature B cell numbers, reactivities and serum Ig levels in mice which simultaneously carry the XID and CD40 deficiency genes. Int Immunol. 8:1996;1675-1685.
75. Khan WN, Nilsson A, Mizoguchi E, Castigli E, Forsell J, Bhan AK, Geha R, Sideras P, Alt FW. Impaired B cell maturation in mice lacking Bruton's tyrosine kinase (Btk) and CD40. Int Immunol. 9:1997;395-405.
76. Kitamura D, Kudo A, Schaal S, Müller W, Melchers F, Rajewsky K. A critical role of λ5 protein in B cell development. Cell. 69:1992;823-831.